Table 2 Organ dysfunction, biological data and treatments during septic shock according to supraventricular arrhythmia occurrence
From: New-onset supraventricular arrhythmia during septic shock: prevalence, risk factors and prognosis
Sinus rhythm (n = 41) | SVA (n = 30) | p | |
|---|---|---|---|
SOFA day 1 | |||
Global (0–24) | 10.0 [7.0–12.5] | 10 [8–16] | 0.369 |
Neurological (0–4) | 1.0 [0.0–4.0] | 1.0 [0.0–4.0] | 0.869 |
Respiratory (0–4) | 2.0 [0.0–4.0] | 2.0 [0.8–3.0] | 0.976 |
Cardiovascular (0–4) | 4.0 [4.0–4.0] | 4.0 [4.0–4.0] | 0.709 |
Renal (0–4) | 1.0 [0.0–2.5] | 2.0 [1.0–4.0] | 0.034 |
Coagulation (0–4) | 0.0 [0.0–1.5] | 1.0 [0.0–2.0] | 0.573 |
Hepatic (0–4) | 0.0 [0.0–2.0] | 0.0 [0.0–1.25] | 0.875 |
Day 1 blood gases | |||
pH | 7.33 [7.21–7.41] | 7.32 [7.24–7.40] | 0.802 |
PCO2, mmHg | 37.0 [29.0–44.5] | 36.0 [30.7–47.5] | 0.692 |
PO2, mmHg | 123.0 [84.5–185.5] | 102.0 [76.0–215.2] | 0.802 |
Bicarbonates, mmol/L | 19.0 [15.9–25.2] | 20.5 [17.0–25.0] | 0.518 |
Lactate, mmol/L | 2.90 [1.43–4.30] | 2.10 [1.40–3.60] | 0.514 |
FIO2, % | 100 [55–100] | 100 [70–100] | 0.910 |
PEEP, cmH2O | 5 [5] | 5 [5] | 0.759 |
Thyroid stimulating hormone, µUI/L | 0.94 [0.35–3.12] | 1.04 [0.34–2.26] | 0.694 |
Cardiac Troponin peak between day 1 and day 3, ng/L | 44 [12.5–295] | 157.5 [22.7–545.8] | 0.222 |
NT proBNP peak between day 1 and day 3, pg/mL | 8092 [2424–32,410] | 15,522 [5987–46209] | 0.229 |
Minimal potassium level during septic shock, mmol/L | 3.3 [2.8–3.7] | 3.2 [2.9–3.4] | 0.571 |
Maximal potassium level during septic shock, mmol/L | 4.6 [4.3–5.2] | 4.5 [4.2–5.1] | 0.771 |
Hemodynamic treatments | |||
Cumulative fluid balance during shock, mL | 5358 [2401–9965] | 4233 [3241–9682] | 0.979 |
Daily fluid balance during shock, mL/day | 2285 [1554–3825] | 1387 [1080–1859] | 0.106 |
Dobutamine use during shock | 8.0 (19.5) | 5 (16.7) | 0.759 |
Dobutamine maximal dose, µg/kg/mina | 5.0 [5.0–13.8] | 10.0 [5.0–12.5] | 0.622 |
Dobutamine maximal dose, µg/kg/min, mean (SD)a | 7.8 (4.9) | 9.0 (4.2) | |
Norepinephrine use during shock | 40 (97.6) | 29 (96.7) | >0.99 |
Norepinephrine maximal dose, mg/ha | 2.9 [1.2–8.0] | 3.3 [2.0–10.0] | 0.210 |
Norepinephrine maximal dose, mg/h, mean (SD)a | 5.1 (5.5) | 6.7 (6.4) | |
Epinephrine use during shock | 3 (7.3) | 3 (10.0) | 0.692 |
Dual catecholamine use during shock | 10 (24.4) | 6 (20.0) | 0.662 |
Length of catecholamine use during shock, days | 3 [2–5] | 4 [3–7] | 0.035 |
Length of vasopressor use during shock, days | 3 [2–5] | 4 [3–7.0] | 0.021 |
Respiratory treatments | |||
Invasive mechanical ventilation | 33 (80.5) | 27 (90.0) | 0.335 |
Mild ARDS | 7 (17.9) | 7 (24.1) | 0.532 |
Moderate to severe ARDS | 17 (41.5) | 11 (36.7) | 0.683 |
Other treatments | |||
Dialysis during shock | 7 (17.1) | 11 (36.7) | 0.061 |
Steroid use during shock | 25 (61.0) | 25 (83.3) | 0.041 |
Steroid use before SVA onset | 25 (61.0) | 14 (46.7) | 0.231 |
Superior vena cava central line in place during shock | 13 (31.7) | 10 (33.3) | 0.885 |